Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252631 | 0.83 | DRD3 (0.47) | KDM4EALDH1A1LMNAGRM5SMN1; SMN2 | |
| SCHEMBL11696997 | 0.83 | HSD17B10 (0.41) | KDM4EALDH1A1LMNAGRM5DAO | |
| SCHEMBL10945571 | 0.80 | MAPT (0.41) | ALDH1A1SMN1; SMN2MRGPRX4POLBMEN1 | |
| SCHEMBL3626897 | 0.80 | GSTP1 (0.49) | KDM4EALDH1A1LMNAGRM5SMN1; SMN2 | |
| SCHEMBL6819751 | 0.80 | GRM5 (0.47) | KDM4EALDH1A1LMNAGRM5SMN1; SMN2 | |
| SCHEMBL30752524 | 0.80 | GRM5 (0.47) | KDM4EALDH1A1LMNAGRM5SMN1; SMN2 | |
| SCHEMBL5253024 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL5254381 | 0.79 | ALDH1A1 (0.35) | KDM4EALDH1A1LMNAGRM5KCNH2 | |
| SCHEMBL2170360 | 0.78 | CA12 (0.42) | KDM4EALDH1A1LMNAPOLBMEN1 | |
| SCHEMBL2088108 | 0.77 | KDM4E (0.49) | KDM4EALDH1A1LMNASMN1; SMN2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-0037729-A2 | Process for penicillin epimerization | ELI LILLY AND COMPANY (US) | 1981-10-14 | — | — | EP | disclosed |
| US-4293495-A | Symmetrical azetidinone aldehyde disulfides and process | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-4293493-A | Azetidinone alcohol disulfides and process for cyclization | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-4115643-A | Process for 3-chloro cephalosporins | ELI LILLY AND COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4060688-A | Cephalosporin intermediates | ELI LILLY AND COMPANY (US) | 1977-11-29 | — | — | US | disclosed |
| US-4044000-A | Substituted β-lactam antibiotics | ELI LILLY AND COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
| US-4012380-A | 7-Acylamino-3-acyl-2(or 3)cephems | ELI LILLY AND COMPANY (US) | 1977-03-15 | — | — | US | disclosed |
| US-4001226-A | 3-(SUBSTITUTED)CARBONYLAMINO CEPHEM DERIVATIVES | ELI LILLY AND COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3994885-A | WITH ALKALI METAL ALKOXIDE, HALOGENATION | ELI LILLY AND COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
| US-3953436-A | 3,4-Dicarboxycephalosporins and derivatives | ELI LILLY AND COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | KDM4E 1125/4885ALDH1A1 2948/4885LMNA 3740/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | KDM4E 3919/4885ALDH1A1 2458/4885LMNA 4860/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | KDM4E 3919/4885ALDH1A1 2458/4885LMNA 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.